https://www.selleckchem.com/products/Y-27632.html
Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have demonstrated antitumor effects in patients with various malignancies, including esophageal cancer. Thus, a better understanding of local immunity in esophageal cancer is crucial for improving treatment and clinical outcomes. We evaluated PD-1 expression on TILs, as well as PD-L1 expression on cancer cells, by immunohistochemistry and immunofluorescence using a non-biased database of 433 curatively resected esophageal cancers. With the idea of application as liquid biopsy
Like
Comment
Share
